|
|
Volumn 368, Issue 3, 2013, Pages 289-290
|
|
Aspirin, PIK3CA mutation, and colorectal-cancer survival [3]
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ACETYLSALICYLIC ACID;
CETUXIMAB;
PANITUMUMAB;
PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE;
CYCLOOXYGENASE 2 INHIBITOR;
PHOSPHATIDYLINOSITOL 3 KINASE;
TUMOR MARKER;
CANCER PROGNOSIS;
CANCER SURVIVAL;
COLORECTAL CANCER;
EXON;
GENE MUTATION;
HUMAN;
LETTER;
LINKAGE ANALYSIS;
METASTASIS;
MOLECULAR MODEL;
MUTATIONAL ANALYSIS;
OVERALL SURVIVAL;
PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHONATE 3 KINASE GENE;
PRIORITY JOURNAL;
TUMOR GENE;
CLINICAL FEATURE;
ENZYME ACTIVATION;
PROTEIN POLYMORPHISM;
COLORECTAL TUMOR;
FEMALE;
GENETICS;
MALE;
NOTE;
ASPIRIN;
COLORECTAL NEOPLASMS;
CYCLOOXYGENASE 2 INHIBITORS;
FEMALE;
HUMANS;
MALE;
PHOSPHATIDYLINOSITOL 3-KINASES;
TUMOR MARKERS, BIOLOGICAL;
|
|
EID: 84872449228
PISSN: 00284793
EISSN: 15334406
Source Type: Journal
DOI: 10.1056/NEJMc1214189 Document Type: Letter |
|
Times cited : (8)
|
|
References (5)
|
